Celltrion Healthcare Co., Ltd.
091990
Hisse Senetlerindeki Sıralama
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Hisse Fiyatı
$57.75
Son senkronizasyon: 2024-01-11
Piyasa Değeri
$9.42B
Değişim (1 gün)
-0.25%
Değişim (1 yıl)
0.00%
Ülke
KR
Ticaret Celltrion Healthcare Co., Ltd. (091990)
Kategori
Healthcare
Celltrion Healthcare Co., Ltd. (091990) için kazanç
2026 itibarıyla kazanç TTM: 0
Celltrion Healthcare Co., Ltd. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Celltrion Healthcare Co., Ltd. için kazanç geçmişi 2014 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2022 | $181.92M | 9.09% |
| 2021 | $166.76M | -42.47% |
| 2020 | $289.85M | 344.13% |
| 2019 | $65.26M | 197.71% |
| 2018 | $21.92M | -89.23% |
| 2017 | $203.63M | 49.87% |
| 2016 | $135.87M | 58.71% |
| 2015 | $85.60M | 781.80% |
| 2014 | $9.71M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
